IPATF - Immunoprecise and LiteVax selects SARS-CoV-2 vaccine candidate

Immunoprecise Antibodies ([[IPATF]]) and LiteVax have nominated a lead COVID-19 vaccine candidate for further (pre-) clinical evaluation and development based on results from their collaborative preclinical immunogenicity study.Immunization of swine with a low dose of the selected candidate resulted in significant serum reactivities towards the SARS-CoV-2 spike protein segment. Furthermore, select formulations were adjuvanted with LiteVax's carbohydrate derivative-based adjuvant to evaluate the potential benefit of co-formulation.No adverse effects were observed for any of the treatment groups.

For further details see:

Immunoprecise and LiteVax selects SARS-CoV-2 vaccine candidate